
The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.
The FDA indication for radium-223 states that patients should have symptomatic disease, though Sartor says he is unsure of the true importance of this. As pain tolerance varies, Sartor says, he does not factor it into his decision — he is more likely to consider the burden of bony disease.




